Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 10/20 | 0.45 |
| ▸ | UBE2M | P61081 | 3/20 | 0.44 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6656007 | 0.95 | OPRM1 (0.46) | DRD2DRD4DRD3OPRM1CHRM2 | |
| SCHEMBL6656905 | 0.92 | CTSS (0.47) | OPRM1CTSSUBE2MDCUN1D1 | |
| SCHEMBL6658372 | 0.92 | CTSS (0.55) | CTSSUBE2MDCUN1D1 | |
| SCHEMBL6652103 | 0.92 | UBE2M (0.47) | OPRM1CHRM2CHRM3CTSSUBE2M | |
| SCHEMBL6655097 | 0.89 | OPRM1 (0.50) | OPRM1CHRM2CHRM3UBE2MDCUN1D1 | |
| SCHEMBL6656589 | 0.88 | OPRM1 (0.49) | OPRM1CHRM2CHRM3UBE2MDCUN1D1 | |
| SCHEMBL6657080 | 0.88 | CTSS (0.58) | CTSS | |
| SCHEMBL6654869 | 0.87 | LMNA (0.46) | OPRM1CHRM2CHRM3UBE2MDCUN1D1 | |
| SCHEMBL6654886 | 0.87 | UBE2M (0.53) | UBE2MDCUN1D1 | |
| SCHEMBL6653818 | 0.85 | UBE2M (0.47) | OPRM1CHRM2CHRM3UBE2MDCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1417202-A2 | AMINOPIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-12 | — | — | EP | claimed |
| US-20030069276-A1 | Amino piperidine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-04-10 | — | — | US | claimed |
| WO-2002079186-A2 | AMINOPIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-10 | — | — | WO | claimed |
| EP-1417202-A2 | AMINOPIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-12 | — | — | EP | disclosed |
| WO-2002079186-A2 | AMINOPIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069276-A1 | Amino piperidine derivatives | CCR5, CCR2, CXCR4 | DRD2 346/4885DRD4 429/4885DRD3 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.